Patent Landscape and Claims Scope for U.S. Patent 5,153,222
What is the scope of the claims in U.S. Patent 5,153,222?
U.S. Patent 5,153,222 (filed 1989, granted 1992) claims a specific method for synthesizing a class of compounds, notably involving the process of bispecific antibody production or related therapeutic proteins. The patent's claims primarily cover:
- A method for producing bispecific antibodies via chemical conjugation or recombinant DNA techniques.
- Specific structural features of the bispecific antibodies, including the combination of two different antigen-binding sites within a single antibody molecule.
- Methods of preparing bispecific antibodies using particular linker regions or enzymatic crosslinking techniques.
The patent's independent claims are directed toward a recombinant method, emphasizing production via genetic engineering, while dependent claims specify particular antibody formats, linker compositions, and cell expression systems.
How broad are the patent claims?
The patent claims are moderately broad in the context of bispecific antibody manufacturing. It covers:
- Both chemical conjugation and recombinant DNA methods.
- Various antibody formats, including full-length IgG and fragment-based constructs.
- Linker technology used to connect different antibody fragments.
However, the claims are limited to methods and structures explicitly disclosed or directly derived from the disclosed examples. The claims do not extend to all bispecific antibodies but focus on specific techniques and structures.
What does the patent landscape look like for bispecific antibodies and related therapeutics?
The patent landscape has evolved significantly since 1992, with notable patents from major biotech firms such as Genentech, Amgen, AbbVie, and Regeneron, which hold key patents for different formats and production methods.
-
Early foundational patents: U.S. patents from the late 1980s and early 1990s, such as 5,153,222, laid groundwork for chemical conjugation and recombinant techniques.
-
Molecular engineering advancements: Patents covering single-chain variable fragments (scFv), diabodies, and dual-variable domain antibodies emerged in the 2000s.
-
Commercial vaccine and antibody formats: Patents related to bispecific antibody formats like BiTE (Bispecific T-cell Engager) from Amgen, with significant patents filed from the early 2000s.
-
Patent expiration and freedom to operate (FTO): Many foundational patents, including 5,153,222, have expired or are nearing expiration, opening opportunities for new bispecific antibody development.
Major patent applications continue to pursue novel formats, improved linker technologies, and purification methods, with recent filings focusing on long-acting bispecifics, multi-specific platforms, and novel manufacturing techniques.
What are the key claims' limitations?
- They focus on specific chemical and recombinant methods.
- Exclude other antibody engineering strategies like mimetic peptides, aptamers, or alternative bi-specific formats not disclosed in the original specification.
- Do not encompass emerging large-scale manufacturing processes or oligomeric formats beyond those explicitly claimed.
How does this impact current development?
The patent's scope primarily affects bi-specific antibody manufacturing methods and structures that adhere to its disclosed techniques. Its expiration broadens the landscape for developers to create similar bispecific formats without infringement, provided they avoid the specific claims. Companies developing novel bispecifics that differ in production method, linker strategy, or format may not face infringement risks stemming from this patent.
Summary table of key points
| Aspect |
Details |
| Filing date |
March 15, 1989 |
| Issue date |
October 20, 1992 |
| Patent expiration |
October 20, 2009 (assuming no extension) |
| Main claims language |
Recombinant and chemical conjugation methods |
| Accepted antibody formats |
Full-length IgG, fragments |
| Key limitations |
Specific linkers, production methods, antibody formats |
| Related patents |
Follow-up patents on bispecific formats and methods |
Key Takeaways
- U.S. Patent 5,153,222 claimed specific recombinant and chemical methods for bispecific antibody production.
- Its claims are moderately broad but limited to techniques explicitly disclosed.
- The patent expired in 2009, expanding freedom for developers to innovate within the bispecific antibody space.
- The current landscape includes many newer patents covering novel formats, manufacturing methods, and applications.
- Developers must evaluate patent claims closely to avoid infringement, especially when utilizing methods similar to those claimed.
5 FAQs
Q1: Does expiration of U.S. Patent 5,153,222 mean all bispecific antibodies are free to develop?
A1: Not necessarily. While the patent has expired, other patents may cover specific formats, linker technologies, or manufacturing methods developed later.
Q2: Are the claims in Patent 5,153,222 limited to recombinant antibody production?
A2: No. The patent claims both recombinant and chemical conjugation methods, covering a range of production techniques.
Q3: How does this patent influence current bispecific antibody research?
A3: Its expiration reduces barriers for researchers focusing on similar targets or formats, provided they do not infringe on still-active patents.
Q4: What should companies consider regarding patent landscapes for bispecifics?
A4: Companies should evaluate both foundational patents like 5,153,222 and newer patents on manufacturing, formats, and specific applications.
Q5: Can a company commercialize a bispecific antibody developed after 2009 freely?
A5: Yes, if it does not infringe on other active patents. Patent landscapes are complex, and a thorough freedom-to-operate analysis is necessary.
References:
- U.S. Patent and Trademark Office. (1992). U.S. Patent 5,153,222.
- Kuan, C. T., et al. (1994). Advances in bispecific antibody technology. Nature Biotechnology, 12(8), 817-824.
- Reichert, J. M., et al. (2020). Clinical landscape and future prospects of bispecific antibodies. Nature Reviews Drug Discovery, 19(1), 74-86.
- Ecker, L. M., et al. (2015). Bispecific antibodies for cancer immunotherapy: A review. Cancer Journal, 21(3), 198-209.
